Phaseline

Companies › IntraBio

IntraBio: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Neurology, Metabolic and endocrine; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trenonacog Alfa (IB1001)
Coagulation factor IX exogenous protein
F9Phase 3Ataxia-Telangiectasia; CACNA1A; Niemann-Pick Disease, Type CDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06673056Trenonacog Alfa (IB1001)Phase 3Ataxia-TelangiectasiaNeurologyDec 2027
NCT07221292Trenonacog Alfa (IB1001)Phase 3CACNA1ANeurologyMay 2028
NCT05163288Trenonacog Alfa (IB1001)Phase 3Niemann-Pick Disease, Type CMetabolic and endocrineJun 2030

Targets

F9 (1)

Companies with the same targets

CSL Behring BioMarin Pharmaceutical Pfizer Roche Shanghai Xinzhi BioMed Baxalta now part of Shire Biocad Regeneron Pharmaceuticals

Companies built like this

Zhejiang Hanmai Pharmaceutical Technology Upsher-Smith Laboratories Urovant Sciences Shenzhen Wingor Biotechnology NeuroBiogen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.